Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sesen Bio Inc is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 35 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.82 |
|---|---|
| 52-week range | $0.37 - $5.03 |
| 50-day moving average | $0.55 |
| 200-day moving average | $0.77 |
| Wall St. target price | $1.78 |
| PE ratio | 2.8996 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.28 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.818 from 2022-06-24
| 1 week (2022-06-17) | 7.63% |
|---|---|
| 1 month (2022-05-25) | 62.14% |
| 3 months (2022-03-23) | N/A |
| 6 months (2021-12-23) | -7.49% |
| 1 year (2021-06-25) | -80.38% |
|---|---|
| 2 years (2020-06-26) | 17.70% |
| 3 years (2019-06-27) | 1.6 |
| 5 years (2017-06-26) | 1.51 |
Valuing Sesen Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sesen Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sesen Bio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Sesen Bio shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $22.2 million |
|---|---|
| Gross profit TTM | $1.2 million |
| Return on assets TTM | -10.56% |
| Return on equity TTM | 59.72% |
| Profit margin | 244.53% |
| Book value | $0.87 |
| Market capitalisation | $163.1 million |
TTM: trailing 12 months
We're not expecting Sesen Bio to pay a dividend over the next 12 months.
Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0.365 up to $5.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 0.8843. This would suggest that Sesen Bio's shares are less volatile than average (for this exchange).
Sesen Bio, Inc. , a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.